
Effects of Vitamin C Supplementation with and Without Endurance Physical Activity on Calcium and Parathyroid Hormone Levels in Metabolic Syndrome Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Abdel Hamid El Bilbeisi^{1,2,4*}, Amany El Afifi³, Halgord Ali M Farag^{4,5}, Mahmoud Taleb³, Riad El Qidra³, Kurosh Djafarian⁴

¹Department of Clinical Nutrition, Faculty of Pharmacy, Al Azhar University of Gaza, Gaza Strip, Palestine

²Department of Nutritional Sciences and Public Health (Academic Department), Palestine Technical College, Gaza Strip, Palestine

³Faculty of Pharmacy, Al Azhar University of Gaza, Gaza Strip, Palestine

⁴Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Science, International Campus (TUMS- IC), Tehran, Iran

⁵Nursing Department, Sulaimani Polytechnic University (SPU), Kurdistan, Iraq

*Corresponding author: Dr. Abdel Hamid El Bilbeisi, Department of Clinical Nutrition, Faculty of Pharmacy, Al Azhar University of Gaza, Gaza Strip, Palestine, Tel: +982188955975; E-mail: abed_az@hotmail.com

Abstract

Background: This study was conducted to determine the effects of vitamin C supplementation with and without endurance physical activity on calcium and parathyroid hormone levels in metabolic syndrome patients.

Methods: In a parallel-randomized, double-blind, placebo-controlled clinical trial, 120 metabolic syndrome patients, was randomly assigned into four groups. Biochemical tests were assessed as baseline and after 12 weeks of intervention. Statistical analysis was performed using SPSS version 20.

Findings: A significant decrease in mean serum calcium levels were seen in participants who received vitamin C or “vitamin C plus 30 minutes/day of physical activity” and “placebo plus 30 minutes/day of physical activity” (p value<0.001). Furthermore, we observed a significant decrease in mean serum levels of parathyroid hormone in participants who received vitamin C or “vitamin C plus 30 minutes/day of physical activity” compared with other two groups (p value<0.001). Also, taking vitamin C plus 30 minutes/day of physical activity, lowered parathyroid hormone more in compared with only taking vitamin C (- 5.77 ± 7.29 vs. - 4.98 ± 9.54).

Conclusions: We conclude that, adding physical activity to vitamin C supplement might be particularly important in regulation of parathyroid hormone and serum calcium levels in metabolic syndrome patients.

Keywords: Calcium; Metabolic syndrome; Physical activity; Parathyroid hormone; Vitamin C

Abbreviations: MetS: Metabolic Syndrome; IDF: International Diabetes Federation; PA: Physical Activity; PTH: Parathyroid Hormone; SD: Standard Deviation; TG: Triglyceride; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; BMI: Body Mass Index; WC: Waist Circumference; FPG: Fasting Plasma Glucose; TC: Total Cholesterol; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol.

Introduction

Metabolic syndrome (MetS) is a cluster of the most dangerous heart attack risk factors: diabetes raised fasting plasma glucose, abdominal obesity, high cholesterol and high blood pressure [1-3]. Based on reports, around 20 to 25 percent of the world's adult population has the MetS [2]. The underlying causes of the MetS have been suggested as central obesity and insulin resistance [4]. Genetic, environmental factors especially unhealthy dietary habits, aging, proinflammatory state, hormonal changes, and physical inactivity contribute to MetS development [5]. Physical inactivity is one of the main factors for chronic diseases which are estimated to cause 1.9 million deaths, globally [6]. In addition, physical inactivity is considered as the fourth leading risk factor for global mortality causing an estimated 3.2 million annual deaths (6% of global deaths) [7]. Physical activity (PA) decreases the risk for premature death, coronary artery disease, obesity, diabetes, hypertension, cancer and depression thereby lowering medical and medication costs and improving quality of life [8].

In addition, inadequate intake of vitamin C and high levels of parathyroid hormone (PTH) may play important roles in cardiovascular risk, which has been suggested to be associated with MetS [9]. Based on the previous studies, doing regular athletic activities and consuming the antioxidants are among the advised solutions for the MetS [10-12]. Furthermore, antioxidant supplementations especially vitamin C relieve the body of the stress associated with MetS and increase the antioxidant capacity [3]. Moreover, physical exercises on a regular basis promote the health of the individuals and its play a vital role in treating MetS patients [13]. During PA, both skeletal muscle and cardiovascular system being active and PTH are widely expressed [14]. Regarding regular PA controversial studies have been reported [15,16]. Some studies have shown that PA associated with increased serum calcium [16,17] conflict studies also has been reported [18,19] and some author found no changes [20]. The liberty of both PTH and calcitonin is reactive to alteration of free ionized calcium and decreased directly after exercise; whereas that, increased PTH levels after acute PA has been confirmed [21]. Indeed, various studies have shown the contradictory effect of vitamin C on PTH secretion, however some of the investigations showed its beneficial property to lower serum PTH level [22,23]. Vitamin C supplementation is possibly a modality to reduce PTH with less side effects, while several investigations have shown, increasing vitamin C levels by dietary supplementation resulted in reduction of PTH in vitamin C deficient individuals [24,25]. In conclusion, adding PA to vitamin C supplement in MetS patients might be particularly important in regulation of PTH and serum calcium levels and reduce the risk of MetS. Our study was conducted to determine the effects of vitamin C supplementation with and without endurance PA on calcium and PTH levels in MetS patients. To the best of our knowledge, this is the first intervention study, which examined this association among MetS patients.

Methods

Study design and participants

This randomized, double-blind, placebo-controlled clinical trial was performed in the Halabja hospital, Kurdistan region of Iraq. The subjects underwent a 12 weeks treatment program (from 01 March 2016 to 23 May 2016). Based on the suggested formulas of this model, the study participants were recruited on the foundation of developed inclusion/exclusion criteria [26]. One hundred-twenty participants were randomly assigned into four groups: Group A received 500 mg/day vitamin C supplements (Morning time), and not participated in 30 minutes/day of endurance PA (n=30); group B received 500 mg/day vitamin C supplements with 30 minutes/day endurance PA (Either at the morning, 7:30 AM or afternoon, after 3:00 PM) (n=30); group C received one placebo of vitamin C/day without endurance PA (n=30); and group D received one placebo of vitamin C/day with 30 minutes/day endurance PA (n=30). All investigators and participants were blinded to the random assignments. Both vitamin C supplements and placebo were obtained from Osweh manufacture Tehran, Iran and was prepared to feature the same shape, odor and size of the supplements.

Participants were asked to use vitamin C supplements and placebos for 12 weeks. Compliance of study

participants with the vitamin C supplements was assessed through quantification of serum vitamin C. To ensure maintenance of their habitual diets throughout the study, all participants provided 3-day dietary recalls (One weekend day and 2 weekdays). Then, we converted the reported portion sizes in the dietary records to grams using household measures. All dietary data were based on the average of three dietary recalls. The grams of food intake data were linked with Nutritionist IV software to derive nutrient intake data. To avoid any confounding effects throughout the study, dietary and PA recommendations were given to all participants at the end of the study.

Sample size and sample determination

-The sample size was calculated using a previously described formula for parallel clinical trials “ $n=2[(z_{1-\alpha/2}+z_{1-\beta})^2 \cdot s^2]/d^2$ ” [26]. In this formula, n is number of participants in each group. For estimating sample size, we considered type one (α) and type two errors (β) of 0.05 and 0.20 (Power=80%) respectively, and fasting plasma glucose levels as a key variable. Based on a previous study, standard deviation (SD) of plasma glucose levels was 8 mg/dL and the difference in mean (d) was considered to be 5 mg/dL. Where $\alpha=0.05$, $\beta=0.20$, study power= 80%, $d=5$, and $SD=8$ ” [26].

$$n = \frac{2(1.96 + 0.85)^2 (8)^2}{(5)^2} = 21$$

We reached the sample size of 21 subjects for each group. To consider probable dropouts, 30 patients were included in each group. Finally, a total of 120 patients with MetS were included in our study. Participants were distributed into four groups as shown in Figure 1.

Inclusion and exclusion criteria

Eligibility criteria for participants having MetS, according to the International Diabetes Federation (IDF) criteria [2], is the age between 30 and 50 years, both gender, living in Halabja for at least three years. Individuals who took supplements containing vitamins C in the last three years were not included in this study. “Individuals with type I and type II diabetes who were taking oral hypoglycemic agents or injecting insulin, or any medical therapy affecting the result, individuals with heart failure, and those who are suffering from renal problems, also individuals with malabsorption syndrome, pregnancy and lactating mothers were all excluded from the study. The exclusion list included patients with history of bariatric surgery and those who are currently using weight loss medications. We also did not include those with a high triglyceride (TG) levels (more than 400 mg/dl) and those with high systolic blood pressure (SBP) or diastolic blood pressure (DBP) (>140/90 mmHg)” [3].

Data collection

At study baseline a standardized questionnaire [27], was used to collect subjects’ information. In addition, the demographic and medical history variables was obtained and recorded with an interview-based questionnaire.

Assessment of physical activity

In the present study, PA for all participants was the same. “Two times a week for climbing (Around 2 hours each time) and two times a week for running (Around one hour in the afternoon between 3 to 5 PM), approximately six hours per week all together” [5].

Assessment of anthropometric measures

Height (m), weight (kg), and waist circumference (WC) were measured according to standard [4]. In addition, the body mass index (BMI) was calculated by dividing weight in kilograms by the square of height in meters. To avoid subjective error, all measurements were taken by the same technician [28]. Blood pressure was measured at morning time in the seated position using a standard mercury sphygmomanometer after at least 15 minutes of rest [29].

Biochemical analysis

Fasting blood samples (10 cc) were collected at baseline and 12 weeks of intervention, after 12 hours overnight fasting to quantify serum levels of fasting plasma glucose (FPG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), TG, vitamin C, serum calcium, and PTH levels. The blood samples were taken using the protocol outlined in [30]. Serum Vitamin C was measured by the Model-vidas analyser (Biomerux, Italy) provided by the clinical laboratory, Slemani Hospital, Iraq. FPG was measured on the day of blood collection by enzymatic colorimetric method using glucose oxidase. Serum TC and TG concentration were assayed using enzymatic colorimetric tests with cholesterol esterase and cholesterol oxidase and glycerol phosphate oxidase, respectively, by using standard kits following manufacturers' protocols. HDL-C was measured after precipitation of the apolipoprotein B containing lipoproteins with phosphotungstic acid. LDL-C was calculated from serum TC, TG and HDL-C based on relevant formula [31]. Finally, serum PTH levels pg/ml were measured using original kits, using perfect plus 400 auto-analyzer (Mindary, UK).

Statistical analysis

All statistical analyses were done using SPSS version 20. Following baseline randomness of allocation of participants in intervention groups by looking at their demographic and medical history characteristics were tested using Chi-square test and ANOVA. After this by student's t-test and paired t-test the difference of variables under study (Change due to intervention), were investigated by adjusting for effects of baseline measures. p value < 0.05 was considered as statistically significant.

Results

Out of the 120 randomized participant at baseline, 47 males and 73 females, overall 24 participants were excluded at the end of the study because of the following reasons: Pregnancy ($n=1$), did not follow recommended PA ($n=8$), poor compliance to vitamin C supplements ($n=6$) and did not complete the study ($n=9$). Finally, 96 participants completed the study and were included in the final analysis. To be confident that age distribution, gender allocation, marital status, and also the family history of obesity, family history of diabetes mellitus and family history of hypertension of participants in different study groups would not alter the findings after the interventions the distribution of above named characteristics compared in study groups at the baseline. Therefore, as demographic characteristics of the participants were not different across intervention groups, so the analysis of different factors at the end of study does not need to be adjusted for these differences. In the present study, the baseline characteristics of the study participants were shown in Table 1. Our results revealed that, comparison of baseline serum vitamin C levels showed no significant difference among the study groups (p value = 0.358). In addition, participants who received vitamin C supplements had higher serum levels of TG compared with those who received placebo or "placebo plus 30 minutes/day of endurance PA" (p value < 0.001). Furthermore, participants in the "vitamin C plus 30 minutes/day of endurance PA" group had higher values of HDL-C compared with those in the placebo group (p value = 0.004). However, participants in the vitamin C group had lower levels of LDL-C compared with those in the "placebo plus 30 minutes/day of endurance PA" group (p value = 0.027). No significant differences among the study groups in terms of age, gender, marital status, weight, BMI, WC, family history of obesity, family history of diabetes mellitus, family history of hypertension, systolic and diastolic blood pressure, FPG, TC, calcium, and PTH levels (p value > 0.05 for all).

On the other hand, the difference of the measured variables between the study groups after 12 weeks of intervention was shown in Table 2. As shown in the table we observed a significant increase in mean serum vitamin C concentrations in participants who received either vitamin C or "vitamin C plus 30 minutes/day of endurance PA" in compared with group took placebo or "placebo plus 30 minutes/day of endurance PA" (p value = 0.001 for all). In addition, a significant decrease in mean serum calcium levels in participants who received either "vitamin C plus 30 minutes/day of endurance PA" or "placebo plus 30 minutes/day of endurance PA" in compared with group took placebo (p value

<0.05 for all). Furthermore, a significant decrease in mean PTH levels in participants who received vitamin C or “vitamin C plus 30 minutes/day of endurance PA” in compared with group took placebo (p value<0.05 for all). Also, taking “vitamin C plus 30 minutes/day of endurance PA” lowered PTH more in compared with only taking vitamin C (-5.77 ± 7.29 vs. -4.98 ± 9.54). Moreover, the end of trial means of vitamin C, calcium, and PTH among study groups is shown in Table 3. After intervention, we observed a significant increase in mean serum vitamin C concentrations in participants who received vitamin C or “vitamin C plus 30 minutes/day of endurance PA” compared with other two groups (p value<0.001). Additionally, we observed a significant decrease in mean serum calcium concentrations in participants who received vitamin C or “vitamin C plus 30 minutes/day of endurance PA” and “placebo plus 30 minutes/day of endurance PA” (p value<0.001). Also, we observed a significant decrease in mean serum levels of PTH in participants who received vitamin C or “vitamin C plus 30 minutes/day of endurance PA” compared with other two groups (p value<0.001).

Finally, the changes in vitamin C, calcium, and PTH in different groups are presented in Table 4. Participants in the “vitamin C plus 30 minutes/day of endurance PA” group had greater changes in vitamin C compared with the other groups (p value<0.001). In addition, a significant change was observed and increased of serum calcium and PTH concentrations in placebo group compared to other groups (p value<0.001 for all). To summarize the findings, analyses showed some of the interventions were effective on decreasing PTH; some interventions increased vitamin C and furthermore decreased calcium levels in MetS patients.

Discussion

To the best of our knowledge, this is the first intervention study, which investigated the effects of vitamin C supplementation along with and without endurance PA on calcium and PTH levels in MetS patients. The main findings of this study indicate that, daily supplementation of vitamin C (500 mg/day), for 12 weeks along with moderate endurance PA had more effects than vitamin C alone, in order to normalize PTH and calcium levels in MetS patients. Various studies have shown the contradictory effect of vitamin C on PTH secretion, however some of the investigations showed its beneficial property to lower serum PTH level [22,23]. However, the interactive effect of vitamin C supplementation along with endurance PA on the keeping calcium and PTH levels to decrease the prevalence of MetS have not yet been concurrently estimated at the level of the general population. Richter and colleagues proposed that there was an inverse interaction between PTH level and vitamin C [22]. In addition, Sanadgol et al. [23] show that, increasing vitamin C levels by dietary supplementation results in a decrease of PTH in vitamin C deficient hemodialysis patients with secondary hyperparathyroidism. The results of our study support these findings. Vitamin C supplementation is possibly a modality to reduce PTH with less side effects, while several investigations have shown, increasing vitamin C levels by dietary supplementation resulted in reduction of PTH in vitamin C deficient individuals [24,25]. Furthermore, investigations have shown, in low serum levels of vitamin C, calcium-sensing receptors may become resistant to PTH effects and, vitamin C increases the response to PTH at the receptor level, through increasing the cyclic adenosine monophosphate and reducing PTH by it [32,33]. Moreover, our findings demonstrate that, after 12 weeks of intervention, taking vitamin C or “vitamin C plus 30 minutes/day of endurance PA”, lowered PTH more in compared with other two groups. Also, taking vitamin C plus 30 minutes/day of endurance PA, lowered PTH more in compared with only taking vitamin C. Evidence from other findings are in line with our finding shows that the synthesis and secretion of PTH increased in response to low vitamin C levels, in order to keep up calcium homeostasis [33]. Other shows no increase in PTH secretion [34], because of “functional hyperparathyroidism” [35] and normal kidney function [36] or may be because of decrease in plasma ionized calcium during PA [37]. Additionally, previous reports had shown that PTH may encourage calcium channel to increase calcium invasion, beside high calcium intake associated with lower PTH levels and decrease the risk of metabolic disease [38,39]. Furthermore, other factors rather than vitamin C such as vitamin D, age, gender, smoking status and serum calcium levels may contribute to PTH levels [40].

On the other hand, our findings revealed that, calcium levels were lowered in those who took vitamin C

or “vitamin C plus 30 minutes/day endurance of PA” and “placebo plus 30 minutes/day of endurance PA”. The inverse relationship between calcium intake and plasma PTH levels has been widely studied at different ages and physiological stages in both humans and animals, in acute and long-term studies [41,42]. In the present study a decrease in calcemia values with the three types of intervention being more notorious for the exercise group than for the vitamin C supplementation group, suggesting an effect of exercise on calcemia, independent of vitamin C. Moreover, a complex relationship between calcium and PTH levels responses to PA have been observed previously [15,43]. Despite the beneficial effect of PA in treatment of low bone mineral density, high intensity PA are resulted in increased ionized calcium, no change in PTH levels, no longer have muscles mass and strength [44,45]. However, the disruption of calcium homeostasis is dependent on the duration of PA [46].

Finally, the findings of the present study shows that, MetS participants with vitamin C supplement plus 30 minutes/day of endurance PA were more PTH suppress in compared with both the placebo groups and those who only took vitamin C. In contrast to our finding, recent studies suggested that, higher levels of PTH were observed in higher physical active young person [42,47]. This change may be because of different in PA duration, age, gender, dietary habits, vitamin and mineral supplementation, as well as the characteristics of participants. Therefore, it need to be answer the hypothesis, if we increase the levels of vitamin C and normalize the PTH levels as well as retaining calcium balance, it is possible to prevent and decrease the prevalence of MetS. For all that, we are inattentive of former investigating in addition to vitamin C, hormones are also correlated with the MetS. Further studies are required.

The strength of the present study is that this is the first study, which investigated the effects of vitamin C supplementation along with and without endurance PA on calcium and PTH levels in MetS patients. Current study has adequate power to detect the significant effects of PA and vitamin C supplement in MetS patients; however, further studies with longer duration of interventions might be needed to confirm the long-term effects of PA and vitamin C supplementation in MetS patients.

Conclusion

In conclusion, adding PA to vitamin C supplement might be particularly important in regulation of PTH and serum calcium levels in MetS patients.

Declarations

Ethical Issues

The Ethics Committee of Tehran University of Medical Sciences approved the study protocol, and the trial was registered at the World Health Organization, International Clinical Trails Registry Platform (Code: IRCT20161110030823N2). In addition, written informed consent was also obtained from each participant.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not: for: profit sectors.

Authors' contributions

AA, HAF, MT, RQ and AHB participated in the design of the study, data collection, performed the statistical analysis and drafted the manuscript. KD and AHB supervising the study and participated in draft review. All authors have read and approved the final version of the manuscript and agree with the order of presentation of the authors.

Acknowledgments

The authors wish to thank and appreciate the staff and participants at Halabja hospital, Kurdistan Region of Iraq for their important participation in the study.

References

1. El Bilbeisi AH, Shab-Bidar S, Jackson D, Djafarian K. The prevalence of metabolic syndrome and its related factors among adults in Palestine: a meta-analysis. *Ethiop J Health Sci* 2017; 27: 77-84.
2. El Bilbeisi AH, Hosseini S, Djafarian K. Dietary patterns and metabolic syndrome among type 2 diabetes patients in Gaza Strip, Palestine. *Ethiop J Health Sci* 2017; 27: 227-238.
3. Farag HAM, Hosseinzadeh-Attar MJ, Muhammad BA, Esmailzadeh A, El Bilbeisi AH. Comparative effects of vitamin D and vitamin C supplementations with and without endurance physical activity on metabolic syndrome patients: a randomized controlled trial. *Diabetol Metab Syndr* 2018; 10: 80.
4. El Bilbeisi AH, Hosseini S, Djafarian K. Association of dietary patterns with diabetes complications among type 2 diabetes patients in Gaza Strip, Palestine: a cross sectional study. *J Health Popul Nutr* 2017; 36: 37.
5. Farag HAM, Hosseinzadeh-Attar MJ, Muhammad BA, Esmailzadeh A, El Bilbeisi AH. Effects of vitamin C supplementation with and without endurance physical activity on components of metabolic syndrome: A randomized, double-blind, placebo-controlled clinical trial. *Clin Nutr Exp* 2019; 26: 23-33.
6. El Bilbeisi AH, Hosseini S, Djafarian K. The association between physical activity and the metabolic syndrome among type 2 diabetes patients in Gaza strip, Palestine. *Ethiop J Health Sci* 2017; 27: 273-282.
7. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. 2009.
8. United States. Department of Health. Physical activity and health: A report of the Surgeon General. DIANE Publishing 1996.
9. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA* 2008; 300: 2123-2133.
10. Ebrahimipour P, Fakhrzadeh H, Heshmat R, Ghodsi M, Bandarian F, et al. Metabolic syndrome and menopause: A population-based study. *Diabetes Metabo Syndr Clin Res Rev* 2010; 4: 5-9.
11. Freiburger E, Häberle L, Spirduso WW, Zijlstra GA. Long-term effects of three multicomponent exercise interventions on physical performance and fall-related psychological outcomes in community-dwelling older adults: a randomized controlled trial. *J Am Geriatr Soc* 2012; 60: 437-446.
12. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. *Nephrology* 2012; 17: 311-321.
13. Strasser B. Physical activity in obesity and metabolic syndrome. *Ann N Y Acad Sci* 2013; 1281: 141-159.
14. Ongkeko WM, Burton D, Kiang A, Abhold E, Kuo SZ, et al. Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer. *PloS One* 2014; 9: e85803.
15. Barry DW, Kohrt WM. Acute effects of 2 hours of moderate-intensity cycling on serum parathyroid hormone and calcium. *Calcif Tissue Int* 2007; 80: 359-365.
16. Goldberg L, Elliot DL. The effect of exercise on lipid metabolism in men and women. *Sports Medicine* 1987; 4: 307-321.
17. Maimoun L, Simar D, Malatesta D, Caillaud C, Peruchon E, et al. Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects. *Br J Sports Med* 2005; 39: 497-502.
18. Maimoun L, Simar D, Caillaud C, Coste O, Barbotte E, et al. Response of calciotropic hormones and bone turnover to brisk walking according to age and fitness level. *J Sci Med Sport* 2009; 12: 463-467.

19. Maïmoun L, Sultan C. Effect of physical activity on calcium homeostasis and calciotropic hormones: a review. *Calcif Tissue Int* 2009; 85: 277-286.
20. Guillemant J, Accarie C, Peres G, Guillemant S. Acute effects of an oral calcium load on markers of bone metabolism during endurance cycling exercise in male athletes. *Calcif Tissue Int* 2004; 74: 407-414.
21. Vaidya A, Curhan GC, Paik JM, Wang M, Taylor EN. Physical activity and the risk of primary hyperparathyroidism. *J Clin Endocrinol Metab* 2016; 101: 1590-1597.
22. Richter A, Kuhlmann MK, Seibert E, Kotanko P, Levin NW, et al. Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. *Nephrol Dial Transplant* 2008; 23: 2058-2063.
23. Sanadgol H, Bayani M, Mohammadi M, Bayani B, Mashhadi MA. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism. *Iran J Kidney Dis* 2011; 5: 410-415.
24. Böhm V, Tiroke K, Schneider S, Sperschneider H, Stein G, et al. Vitamin C status of patients with chronic renal failure, dialysis patients and patients after renal transplantation. *J Int Vitam Nutr Res* 1997; 67: 262-266.
25. Deicher R, Ziai F, Bieglmayer C, Schillinger M, Hörl WH. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. *J Am Soc Nephrol* 2005; 16: 1811-1818.
26. Farag HA, Hosseinzadeh-Attar MJ, Muhammad BA, Esmailzadeh A, el Bilbeisi AH. Effects of vitamin D supplementation along with endurance physical activity on lipid profile in metabolic syndrome patients: A randomized controlled trial. *Diabetes Metabo Syndr Clin Res Rev* 2019; 13: 1093-1038.
27. Aalto AM, Elovainio M, Kivimäki M, Uutela A, Pirkola S. The Beck Depression Inventory and General Health Questionnaire as measures of depression in the general population: a validation study using the Composite International Diagnostic Interview as the gold standard. *Psychiatry Res* 2012; 197: 163-171.
28. El Bilbeisi AH, Albelbeisi A, Hosseini S, Djafarian K. Dietary Pattern and Their Association With Level of Asthma Control Among Patients With Asthma at Al-Shifa Medical Complex in Gaza Strip, Palestine. *Nutr Metab Insights* 2019; 12: 1178638819841394.
29. El Bilbeisi AH, Hosseini S, Djafarian K. Dietary Patterns and Their Association with Blood Pressure Control among Hypertensive Patients in Gaza Strip, Palestine. *J Fam Med Health Care* 2018; 4: 5-12.
30. Bull SM. Evidence-Based Blood Conservation Education for ICU Nurses: A Pre and Post-Test Evaluation of Nursing Knowledge. 2014.
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
32. McCauley LK, Koh AJ, Beecher CA, Cui Y, Rosol TJ, et al. PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis. *J Cell Biochemistry* 1996; 61: 638-647.
33. Friedman PA, Coutermarsh BA, Kennedy SM, Gesek FA. Parathyroid hormone stimulation of calcium transport is mediated by dual signaling mechanisms involving protein kinase A and protein kinase C. *Endocrinology* 1996; 137: 13-20.
34. Sahota O, Munday MK, San P, Godber IM, Lawson N, et al. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. *Bone* 2004; 35: 312-319.
35. Sahota O, Gaynor K, Harwood RH, Hosking DJ. Hypovitaminosis D and 'functional hypoparathyroidism'—the NoNoF (Nottingham Neck of Femur) study. *Age Ageing* 2001; 30: 467-472.
36. Patel S, Hyer S, Barron J. Glomerular filtration rate is a major determinant of the relationship between 25-hydroxyvitamin D and parathyroid hormone. *Calcif Tissue Int* 2007; 80: 221-226.
37. Ljunghall S, Joborn H, Roxin LE, Rašad J, Wide L, et al. Prolonged low-intensity exercise raises the serum parathyroid hormone levels. *Clin endocrinol* 1986; 25: 535-542.

38. Lin PH, Ginty F, Appel LJ, Aickin M, Bohannon A, et al. The DASH diet and sodium reduction improve markers of bone turnover and calcium metabolism in adults. *J Nutr* 2003; 133: 3130-3136.
39. Sadideen H, Swaminathan R. Effect of acute oral calcium load on serum PTH and bone resorption in young healthy subjects: an overnight study. *Eur J Clin Nutr* 2004; 58: 1661-1665.
40. Björkman M, Sorva A, Tilvis R. Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. *Arch of Gerontol Geriatr* 2009; 48: 160-166.
41. Chan R, Chan D, Woo J, Ohlsson C, Mellström D, et al. Serum 25-hydroxyvitamin D and parathyroid hormone levels in relation to blood pressure in a cross-sectional study in older Chinese men. *J Hum Hypertens* 2012; 26: 20-27.
42. Schoenmakers I, Jarjou LM, Goldberg GR, Tsoi K, Harnpanich D, et al. Acute response to oral calcium loading in pregnant and lactating women with a low calcium intake: a pilot study. *Osteoporos Int* 2013; 24: 2301-2308.
43. Scott JP, Sale C, Greeves JP, Casey A, Dutton J, et al. The role of exercise intensity in the bone metabolic response to an acute bout of weight-bearing exercise. *J Appl Physiol* 2010; 110: 423-432.
44. Salvesen H, Johansson AG, Foxdal P, Wide L, Piehl-Aulin K, et al. Intact serum parathyroid hormone levels increase during running exercise in well-trained men. *Calcif Tissue Int* 1994; 54: 256-261.
45. Gallagher JC, Yalamanchili V, Smith LM. The effect of vitamin D supplementation on serum 25OHD in thin and obese women. *J Steroid Biochem Mol Biol* 2013; 136: 195-200.
46. Ljunghall S, Joborn H, Benson L, Fellström B, Wide L, et al. Effects of physical exercise on serum calcium and parathyroid hormone. *Eur J Clin Invest* 1984; 14: 469-473.
47. Townsend R, Elliott-Sale KJ, Pinto AJ, Thomas C, Scott JP, et al. Parathyroid hormone secretion is controlled by both ionized calcium and phosphate during exercise and recovery in men. *J Clin Endocrinol Metab* 2016; 101: 3231-3239.

Table 1: Baseline characteristics of study participants.

Variables	Group (n=96)				p value ⁶
	Vitamin C ² (n=26)	Vitamin C+PA ³ (n=23)	Placebo ⁴ (n=25)	Placebo+PA ⁵ (n=22)	
Age (years)	41.19 ± 5.8	40.78 ± 5.8	42.60 ± 5.6	41.59 ± 6.4	0.125
Female (%)	16.0 (61.5)	16.0 (69.6)	12.0 (48.0)	13.0 (59.1)	0.71
Married (%)	22.0 (84.6)	19.0 (82.6)	21.0 (84.0)	17.0 (77.3)	0.155
Weight (kg)	81.04 ± 13.1	79.72 ± 13.5	82.34 ± 13.9	74.84 ± 12.6	0.467
Body mass index (kg/m ²)	31.96 ± 6.0	32.34 ± 5.8	32.81 ± 4.3	30.13 ± 4.7	0.654
Waist circumference (cm)	108.2 ± 10.4	107.8 ± 8.7	107.6 ± 9.6	111.4 ± 10.2	0.563
Family history of obesity (%)	17.0 (65.4)	15.0 (65.2)	19.0 (76.0)	11.0 (50.0)	0.427
Family history of diabetes mellitus (%)	12.0 (46.2)	8.0 (34.8)	15.0 (60.0)	9.0 (40.9)	0.754
Family history of hypertension (%)	12.0 (46.2)	13.0 (56.5)	15.0 (60.0)	9.0 (40.9)	0.326
Systolic blood pressure (mmHg)	130.1 ± 11.9	128.9 ± 11.3	125.6 ± 14.5	128.6 ± 10.8	0.806
Diastolic blood pressure (mmHg)	81.3 ± 8.3	79.3 ± 7.1	80.0 ± 6.9	82.5 ± 5.9	0.523

Fasting plasma glucose (mg/dl)	106.6 ± 19.9	103.9 ± 13.6	110.6 ± 17.2	106.2 ± 18.1	0.635
Total cholesterol (mg/dl)	174.7 ± 41.5	178.2 ± 29.7	185.9 ± 39.0	194.0 ± 35.7	0.771
Triglycerides (mg/dl)	268.4 ± 107.1*	176.1 ± 87.3	147.3 ± 42.9	161.6 ± 70.1	0.001
HDL-C (mg/dl)	33.06 ± 13.4	37.61 ± 11.0†	30.04 ± 8.5	40.81 ± 16.5	0.004
LDL-C (mg/dl)	114.4 ± 47.4‡	135.5 ± 32.6	150.4 ± 39.8	153.5 ± 38.3	0.027
Vitamin C (ng/ml)	0.86 ± 0.37	0.78 ± 0.29	0.95 ± 0.31	0.92 ± 0.34	0.358
Calcium (mg/dl)	9.56 ± 1.2	9.15 ± 1.0	9.33 ± 1.2	9.63 ± 1.0	0.498
Parathyroid hormone (pg/ml)	59.3 ± 10.6	52.6 ± 11.2	49.2 ± 12.3	54.7 ± 17.3	0.806

¹Data are mean ± standard deviation (SD)
²Receiving 500 mg vitamin C per day
³Receiving 500 mg vitamin C per day plus 30 minutes endurance physical activity
⁴Receiving one placebo per day
⁵Receiving one placebo per day plus 30 minutes endurance physical activity
⁶Obtained from ANOVA or chi-square test, where appropriate
*P<0.05 compared with the other groups, using Tukey's test
†P<0.05 compared with the placebo group, using Tukey's test
‡P<0.05 compared with the placebo plus physical activity group, using Tukey's test
PA: Physical activity

Table 2: Difference of the measured variables between the groups at 12 weeks of intervention.

Variables	Vitamin C2 (n=26)		p value ⁶	Vitamin C+PA3 (n=23)		p value ⁶
	Before	After		Before	After	
	Mean ± SD	Mean ± SD		Mean ± SD	Mean ± SD	
Vit C (ng/ml)	0.86 ± 0.37	1.36 ± 0.28	0.001	0.78 ± 0.29	1.66 ± 0.33	0.001
Ca (mg/dl)	9.56 ± 1.2	9.41 ± 0.8	0.319	9.15 ± 1.0	8.82 ± 1.6	0.028
PTH (pg/ml)	59.3 ± 10.6	54.3 ± 10.6	0.006	52.6 ± 11.2	46.83 ± 8.3	0.001
Variables	Placebo4 (n=25)		p value ⁶	Placebo+PA5 (n=22)		Variables p value ⁶
	Before	After		Before	After	
	Mean ± SD	Mean ± SD		Mean ± SD	Mean ± SD	
Vit C (ng/ml)	0.95 ± 0.31	0.88 ± 0.35	0.475	0.92 ± 0.34	1.07 ± 0.29	0.144
Ca (mg/dl)	9.33 ± 1.2	9.61 ± 1.0	0.041	9.63 ± 1.0	9.23 ± 0.5	0.015
PTH (pg/ml)	49.2 ± 12.3	54.61 ± 8.6	0.021	54.7 ± 17.3	52.8 ± 11.0	0.406

¹Data are means ± standard deviation (SD)
²Receiving 500 mg vitamin C per day
³Receiving 500 mg vitamin C per day plus 30 minutes' endurance physical activity
⁴Receiving one placebo per day
⁵Receiving one placebo per day plus 30 minutes endurance physical activity
⁶Obtained from paired sample T test
*P<0.05 are significant
PA: Physical activity; PTH: Parathyroid hormone; Vit C: Vitamin C; Ca: Calcium

Table 3: End of trial means of vitamin C, calcium, and parathyroid hormone across study groups.1


Groups (96)					
Variables	Vitamin C2 (n=26)	Vitamin C+PA3 (n=23)	Placebo4 (n=25)	Placebo+PA5 (n=22)	p-value6
Vitamin C (ng/ml)	1.36 ± 0.28	1.66 ± 0.33	0.88 ± 0.35	1.07 ± 0.29	0.001
Calcium (mg/dl)	9.41 ± 0.8	8.82 ± 1.6	9.61 ± 1.0	9.23 ± 0.5	0.001
PTH (pg/ml)	54.32 ± 10.6	46.83 ± 8.3	54.61 ± 8.6	52.81 ± 11.0	0.001

¹Data are means ± standard deviation (SD)
²Receiving 500 mg vitamin C per day
³Receiving 500 mg vitamin C per day plus 30 minutes endurance physical activity
⁴Receiving one placebo per day
⁵Receiving one placebo per day plus 30 minutes endurance physical activity
⁶Obtained from ANOVA
PA: Physical activity; PTH: Parathyroid hormone

Table 4: Changes in vitamin C, calcium, and parathyroid hormone in different groups.

Variables	Vitamin C2 (n=26)	Vitamin C+PA3 (n=23)	Placebo4 (n=25)	Placebo+PA5 (n=22)	p-value6
Vitamin C (ng/ml)	0.49 ± 91	0.88 ± 04*	0.06 ± 96	0.14 ± 95	0.001
Calcium (mg/dl)	-0.15 ± 0.04	-0.32 ± 0.94	0.27 ± 0.98*	-0.40 ± 0.05	0.001
PTH (pg/ml)	-4.98 ± 9.54	-5.77 ± 7.29	5.40 ± 0.63*	-1.90 ± 0.62	0.001

¹Data are means ± standard deviation (SD)
²Receiving 500 mg vitamin C per day
³Receiving 500 mg vitamin C per day plus 30 minutes endurance physical activity
⁴Receiving one placebo per day
⁵Receiving one placebo per day plus 30 minutes endurance physical activity
⁶Obtained from ANOVA
PA: Physical activity; PTH: Parathyroid hormone

**Figure 1:** Participant's flow diagram.